6505--Hydroxychloroquine SO4 Tablets
ID: 36E79725R0022Type: Presolicitation
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNAC PHARMACEUTICALS (36E797)HINES, IL, 60141, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/6a60797d7d15409792dedbbb59d9d510/view
Timeline
    Description

    The Department of Veterans Affairs (VA) is issuing a Request for Proposal (RFP) for the procurement of Hydroxychloroquine SO4 Tablets, aimed at ensuring a continuous supply for various federal entities, including the Department of Defense and the Bureau of Prisons. The contract will cover an estimated annual requirement of 163,395 bottles of 100-count and 25,853 bottles of 500-count Hydroxychloroquine tablets, with a contract period of one year and four optional one-year extensions. This procurement is critical for maintaining essential medications within veteran and federal healthcare programs. Interested parties should monitor SAM.gov for updates and direct inquiries to the contracting officer, Chris Carthron, at Christopher.Carthron@va.gov or (708) 786-4980, with submissions due by March 26, 2025.

    Point(s) of Contact
    Chris CarthronContracting Officer
    (708) 786-4980
    Christopher.Carthron@va.gov
    Files
    Title
    Posted
    36E79725R0022_2.docx
    The Department of Veterans Affairs (VA) is issuing a Request for Proposal (RFP) 36E79725R0022 for an unrestricted procurement of Hydroxychloroquine SO4 Tablets. This procurement serves various federal entities, including the Department of Defense, Bureau of Prisons, and Indian Health Service. The contract period spans one year with four optional one-year extensions, aimed at ensuring a continuous supply of the drug. Offerors must provide their unique National Drug Code (NDC) without labeling over existing labels. The solicitation will be available electronically on or around March 12, 2025, with submissions due by March 26, 2025. The estimated annual requirements total 163,395 bottles of 100-count and 25,853 bottles of 500-count Hydroxychloroquine tablets. Interested parties must monitor SAM.gov for updates and communicate with the contracting officer, Chris Carthron, for inquiries. This RFP reflects the VA's ongoing efforts to secure essential medications for veteran and federal healthcare programs.
    Lifecycle
    Title
    Type
    6505--Hydroxychloroquine SO4 Tablets
    Currently viewing
    Presolicitation
    Similar Opportunities
    6505--Mycophenolate Mofetil RFP
    Buyer not available
    The Department of Veterans Affairs is seeking proposals for the procurement of Mycophenolate Mofetil capsules and tablets under Solicitation Number 36E79725R0010, aimed at establishing national pricing for these pharmaceutical products. The contract is intended to support various government health care facilities, including those under the Department of Defense and Indian Health Service, ensuring compliance with FDA standards and the Drug Supply Chain Security Act. Offerors are required to submit pricing for both the base year and four option years, with a deadline for submissions extended to March 4, 2025, at 2:30 PM CST, and must acknowledge receipt of this amendment to avoid rejection of their offers. Interested parties can contact Contract Specialist Amber Zavala at amber.zavala@va.gov for further information.
    6505--Insulin (VA-25-00026482)
    Buyer not available
    The Department of Veterans Affairs (VA) is issuing a presolicitation notice for Request for Proposal (RFP) 36E79725R0018, aimed at procuring human insulin for various federal agencies, including the Department of Defense and the Bureau of Prisons. The procurement seeks an uninterrupted supply of insulin over a one-year period, with the possibility of extending the contract for four additional one-year options, and includes specific technical requirements such as individual packaging with barcodes and compatibility with automated dispensing units. This initiative underscores the VA's commitment to ensuring a consistent supply of essential medications for federal health services. Interested offerors should monitor the SAM.gov site for updates, as the solicitation will be available electronically around March 4, 2025, with proposals due by March 18, 2025; inquiries can be directed to Contract Specialist Billy Fong at billy.fong@va.gov or by phone at 708-786-4992.
    6505--Fluticasone Propionate 50 MCG/Spray Soln, Nasal, 16GM
    Buyer not available
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Fluticasone Propionate 50 MCG/Spray solution, nasal, 16GM, intended for use by various federal agencies including the Department of Defense, Bureau of Prisons, and Indian Health Service. The objective of this procurement is to secure a reliable and uninterrupted supply of this medication for a contract period of one year, with the possibility of four additional one-year extensions. This medication is crucial for treating nasal conditions, and the estimated annual requirement is approximately 5,784,828 bottles. The solicitation will be available electronically on or around February 11, 2025, with a closing date set for February 25, 2025. Interested vendors should direct inquiries to Michael Olszewski at michael.olszewski@va.gov or call 708-786-4966.
    6505--Tamsulosin Capsules
    Buyer not available
    The Department of Veterans Affairs is soliciting proposals for the procurement of Tamsulosin Hydrochloride capsules, aimed at establishing a reliable supply source for pharmaceutical products under the Pharmaceutical Prime Vendor (PPV) Programs. The contract will cover a base year with four optional extension years, requiring offerors to provide pricing for each year, along with a 0.5% Cost Recovery Fee and a unique National Drug Code (NDC) for each product. This procurement is crucial for ensuring that federal healthcare facilities have consistent access to necessary pharmaceuticals while adhering to regulatory standards, including compliance with the Drug Supply Chain Security Act (DSCSA) and Good Manufacturing Practices (cGMP). Interested parties should note that the deadline for submitting offers has been extended to February 27, 2025, at 2:30 PM CST, and can contact Contract Specialist Andrew J Cazares at Andrew.Cazares@va.gov for further information.
    6505--Phenytoin SA Capsules (VA-25-00022318)
    Buyer not available
    The Department of Veterans Affairs is soliciting proposals for the supply of Phenytoin Sodium (NA) Extended 100MG Sustained Action Capsules under solicitation number VA-25-00022318. This procurement aims to secure a reliable supply of essential medications for the VA and Department of Defense’s Pharmaceutical Prime Vendor Programs, ensuring consistent access to pharmaceuticals for federal health care facilities. Offerors must comply with federal regulations, including the Drug Supply Chain Security Act, and provide unique 11-digit National Drug Code numbers along with a Letter of Commitment from manufacturers. The deadline for submitting proposals has been extended to February 27, 2025, at 2:30 PM Central Time, and interested parties should contact Contract Specialist Youlanda Duggar at youlanda.duggar@va.gov for further information.
    6505--Diclofenac Sodium (NA) 1% Gel
    Buyer not available
    The Department of Veterans Affairs (VA) is soliciting proposals for the supply of Diclofenac Sodium (NA) 1% Gel, intended for use in its pharmaceutical programs as well as those of the Department of Defense (DoD). Contractors are required to provide pricing for a base year along with four one-year option years, ensuring compliance with federal drug regulations and the Drug Supply Chain Security Act (DSCSA). This procurement is critical for maintaining a reliable supply of pharmaceutical products that meet stringent manufacturing standards and public health requirements. Interested parties must submit their offers by March 4, 2025, at 2:30 PM Central Time, and can contact Contract Specialist Ray Roldan at Raymond.Roldan@va.gov for further information.
    Valsartan
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Valsartan, a drug used to treat high blood pressure and heart failure. The contract will include Valsartan tablets in various strengths and quantities. It will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The solicitation will be posted on the DLA Bid Board System and beta.SAM.gov, with a projected solicitation date in June 2021. Interested parties should contact Christopher Newman for more information.
    6505--Rituximab and Biosimilars
    Buyer not available
    The Department of Veterans Affairs is soliciting proposals for the procurement of Rituximab 10mg/ml and its biosimilars, aimed at establishing a reliable pharmaceutical supply source for government healthcare facilities. Bidders are required to provide unique National Drug Code (NDC) numbers for their products and include a 0.5% Cost Recovery Fee in their pricing, with the contract covering a base year and four optional subsequent years. This procurement is critical for ensuring consistent product availability and pricing based on estimated annual usage, while adhering to FDA regulations and the Drug Supply Chain Security Act (DSCSA) for safety and traceability. Interested suppliers must submit their proposals by March 11, 2025, at 2:30 PM CT, and can contact Contract Specialist Deborah S Fassl at Deborah.Fassl@va.gov for further information.
    Doxycycline Hyclate
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Doxycycline Hyclate. The contract will establish a national supply source to provide Doxycycline Hyclate 100MG Tablets in various bottle sizes. This acquisition is for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be firm-fixed price, requirements type with a one year base and four one year options. Interested parties should contact Catherine Gilbert for more information. The projected solicitation date is September 2019.
    6505--Bevacizumab Injection
    Buyer not available
    The Department of Veterans Affairs is soliciting proposals for the procurement of Bevacizumab injections, a critical pharmaceutical product used in various healthcare settings for veterans. Vendors are required to meet specific criteria, including providing unique National Drug Codes (NDC) and adhering to the Drug Supply Chain Security Act regulations, as the contract aims to ensure a reliable supply of this medication across government health care facilities. The selected contractor will be responsible for multiple line items of different Bevacizumab formulations, maintaining compliance with FDA manufacturing practices, and submitting quarterly sales reports, including cost recovery fees. Interested vendors should contact Contract Specialist Matthew S. Poulin at Matthew.Poulin@va.gov for further details, with submissions due by the specified deadlines outlined in the solicitation document.